ABCDx today announced the publication of new pediatric traumatic brain injury research in Frontiers in Neurology, further strengthening the scientific foundation of its blood-based biomarker portfolio for traumatic brain injury.
The study, led by Dr. Anne-Cécile Chiollaz and Prof. Jean-Charles Sanchez with Swiss pediatric clinical partners, identifies interleukin-10(IL-10) as a promising early blood biomarker associated with persistent post-concussion symptoms in children after mild traumatic brain injury.
Persistent post-concussion symptoms remain difficult to predict at emergency department discharge. Today, clinicians lack objective tools to identify which children are most likely to need structured neuropsychological follow-up. In this exploratory study, IL-10 measured within24 hours of injury was significantly elevated in children with symptoms persisting at both 14 days and 3 months, with an AUC of 79.9% for predicting persistent symptoms.
“These findings add an important pediatric dimension to our translational TBI research,” said Prof. Jean-Charles Sanchez, Professor at the Faculty of Medicine, University of Geneva and founder ofABCDx. “Together with our adult and pediatric clinical studies, publication sand intellectual property, this work reinforces the potential of blood biomarkers to transform traumatic brain injury management from subjective assessment toward objective, biology-based triage and follow-up.”
The publication complements ABCDx’s broader scientific and patent portfolio in traumatic brain injury, including biomarkers such as GFAP,H-FABP, S100b, NfL, NT-proBNP, IL-6 and IL-10. It also supports the company’s strategy to develop blood-based diagnostic and triage tools for acute neurological conditions, with potential applications in emergency departments, pediatric care and future point-of-care testing.
“Children with mild traumatic brain injury represent a major unmet medical need,” said Dr. Anne-Cécile Chiollaz, first author of the study. “An early blood biomarker that helps identify those at risk of persistent symptoms could improve follow-up decisions and reduce unnecessary burden on families and healthcare systems.”
ABCDx considers this publication an important additional validation of its translational approach: combining clinically relevant biomarkers, prospective patient cohorts and acute-care workflows to develop future diagnostic products.
The authors emphasize that the findings remain exploratory and require confirmation in larger independent cohorts before clinical implementation.
About ABCDx
ABCDx is a Swiss-Spanish medtech company developing blood-based point-of-care diagnostics and digital tools for acute neurological and cardiovascular emergencies. Its mission is to improve triage, diagnosis and clinical decision-making through biomarker-driven and AI-enabled solutions.
MediaContact
Tamara Sefcovicova
PR, Marketing andOffice Operations Specialist
